TITLE

High-resolution melting analysis for detection of familial ligand-defective apolipoprotein B-100 mutations

AUTHOR(S)
Liyanage, Khemanganee E; Hooper, Amanda J; Defesche, Joep C; Burnett, John R; van Bockxmeer, Frank M
PUB. DATE
March 2008
SOURCE
Annals of Clinical Biochemistry;Mar2008, Vol. 45 Issue 2, p170
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Familial ligand-defective apolipoprotein B-100 (FDB) is characterized by elevated plasma concentrations of LDL-cholesterol and apolipoprotein (apo) B, normal triglyceride and HDL-cholesterol levels, the presence of tendon xanthomas, and premature coronary artery disease. FDB cannot be clinically distinguished from heterozygous LDL-receptor-defective familial hypercholesterolaemia (FH) without genetic testing. Methods: Amplicons in exon 26 and exon 29 of the APOB gene were screened for established genetic variants including mutations and polymorphisms using high-resolution melting analysis. Six novel variants associated with FDB in hypercholesterolaemic Dutch patients (S3476L, S3488G, Y3533C, T3540M, I4350T, G4368D) were also studied. Results: All positive controls, a total of 10 mutations in exon 26 and four mutations in exon 29, were readily detectable by melting curve analysis. In addition, a patient previously not known to be heterozygous for the H3543Y mutation was identified in a screen of hypercholesterolaemic subjects. The method was validated by comparison of high-resolution melting analysis with DNA sequence data in a 'blinded' manner in 35 consecutive patients attending a lipid disorders clinic. These patients were classified as 'definite FH' by the Dutch Lipid Clinic Network criteria. Five patients were found to be heterozygous for the R3500Q and one for H3543Y. Conclusions: We have established a novel, robust method of FDB mutation detection using high-resolution melting analysis in conjunction with DNA sequencing. Compared with existing methods it is not only more cost-effective, but is also capable of detecting new sequence changes and will have importance in cascade screening of affected subjects.
ACCESSION #
31139842

 

Related Articles

  • Study of apolipoprotein E polymorphism in normal healthy controls from Northern India. Chhabra, S.; Agarwal, D.P.; Vasisht, S.; Luthra, K.; Narang, R.; Manchanda, S.C.; Srivastava, L.M.; Das, N. // Disease Markers;2000, Vol. 16 Issue 3/4, p159 

    Presents information on a study which investigated apolipoprotein (apo) E polymorphism in a group of healthy volunteers in India. Incidence of coronary artery disease among Asian Indians; Genotypic and allelic distribution of apo E; Occurrence of hypercholesterolemia.

  • Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Abifadel, Marianne; Varret, Mathilde; Rabes, Jean-Pierre; Allard, Delphine; Ouguerram, Khadija; Devillers, Martine; Cruaud, Corinne; Benjannet, Suzanne; Wickham, Louise; Erlich, Daniele; Derre, Aurelie; Villeger, Ludovic; Farnier, Michel; Beucler, Isabel; Bruckert, Eric; Chambaz, Jean; Chanu, Bernard; Lecerf, Jean-Michel; Luc, Gerald // Nature Genetics;Jun2003, Vol. 34 Issue 2, p154 

    Autosomal dominant hypercholesterolemia (ADH; OMIM144400), a risk factor for coronary heart disease, is characterized by an increase in low-density lipoprotein cholesterol levels that is associated with mutations in the genes LDLR (encoding low-density lipoprotein receptor) or APOB (encoding...

  • Rosuvastatin Reduces Plasma Small Dense LDL-Cholesterol Predominantly in Non-Diabetic Hypercholesterolemic Patients. Yoshino, Gen; Nakano, Saburo; Matsumoto, Tomoko; Murakami, Eiichi; Morita, Toshisuke; Kuboki, Koji // Pharmacology & Pharmacy;Jan2012, Vol. 3 Issue 1, p72 

    Aims: Small dense LDL (sdLDL) cholesterol is considered a cardiovascular risk. Our purpose in this study was to evaluate the efficacy of rosuvastatin in reducing sdLDL and large buoyant LDL (lbLDL-C) in hypercholesterolemia. Methods: Fifty-six patients with a mean baseline LDL-cholesterol...

  • Common genetic variants do not associate with CAD in familial hypercholesterolemia. van Iperen, Erik P A; Sivapalaratnam, Suthesh; Boekholdt, S Matthijs; Hovingh, G Kees; Maiwald, Stephanie; Tanck, Michael W; Soranzo, Nicole; Stephens, Jonathan C; Sambrook, Jennifer G; Levi, Marcel; Ouwehand, Willem H; Kastelein, John JP; Trip, Mieke D; Zwinderman, Aeilko H // European Journal of Human Genetics;Jun2014, Vol. 22 Issue 6, p809 

    In recent years, multiple loci dispersed on the genome have been shown to be associated with coronary artery disease (CAD). We investigated whether these common genetic variants also hold value for CAD prediction in a large cohort of patients with familial hypercholesterolemia (FH). We genotyped...

  • Homozygous familial hypercholesterolemia. M. K., ALICEZAH; R., RAZALI; T., RAHMAN; B. P., HOH; N. H., SUHANA; V., MUID S.; NAWAWI, HM; KOSHY, M. // Malaysian Journal of Pathology;Aug2014, Vol. 36 Issue 2, p131 

    We report a rare case of homozygous familial hypercholesterolemia (HoFH), a 22-year-old Malay woman who presented initially with minor soft tissue injury due to a cycling accident. She was then incidentally found to have severe xanthelasma and hypercholesterolemia (serum TC 15.3 mmol/L and LDL-C...

  • Genetic Testing of Korean Familial Hypercholesterolemia Using Whole-Exome Sequencing. Han, Soo Min; Hwang, Byungjin; Park, Tae-gun; Kim, Do-Il; Rhee, Moo-Yong; Lee, Byoung-Kwon; Ahn, Young Keun; Cho, Byung Ryul; Woo, Jeongtaek; Hur, Seung-Ho; Jeong, Jin-Ok; Park, Sungha; Jang, Yangsoo; Lee, Min Goo; Bang, Duhee; Lee, Ji Hyun; Lee, Sang-Hak // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Familial hypercholesterolemia (FH) is a genetic disorder with an increased risk of early-onset coronary artery disease. Although some clinically diagnosed FH cases are caused by mutations in LDLR, APOB, or PCSK9, mutation detection rates and profiles can vary across ethnic groups. In this study,...

  • Haplotype analyses, mechanism and evolution of common double mutants in the human LDL receptor gene. Tejedor, M. T.; Cenarro, A.; Tejedor, D.; Stef, M.; Mateo-Gallego, R.; De Castro, I.; García-Otin, A. L.; Monteagudo, L. V.; Civeira, F.; Pocovi, M. // Molecular Genetics & Genomics;Jun2010, Vol. 283 Issue 6, p565 

    Familial hypercholesterolemia (FH), an autosomal dominant inherited disorder resulting in increased levels of circulating plasma low-density lipoprotein (LDL), tendon xanthomas and premature coronary artery disease (CAD), is caused by defects in the LDL receptor gene ( LDLR). Three widespread...

  • Identification of a recurrent insertion mutation in the LDLR gene in a Pakistani family with autosomal dominant hypercholesterolemia. Ajmal, Muhammad; Ahmed, Waqas; Sadeque, Ahmed; Ali, Syeda; Bokhari, Syed; Ahmed, Nuzhat; Qamar, Raheel // Molecular Biology Reports;Dec2010, Vol. 37 Issue 8, p3869 

    Familial Hypercholesterolemia (FH) results in elevated levels of blood lipids including total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) with normal triglycerides (TG). This disease is one of the major contributors towards an early onset of coronary heart disease (CHD). The...

  • Genetic Causes of Monogenic Heterozygous Familial Hypercholesterolemia: A HuGE Prevalence Review. Austin, Melissa A.; Hutter, Carolyn M.; Zimmern, Ron L.; Humphries, Steve E. // American Journal of Epidemiology;Sep2004, Vol. 160 Issue 5, p407 

    The clinical phenotype of heterozygous familial hypercholesterolemia (FH) is characterized by increased plasma levels of total cholesterol and low density lipoprotein cholesterol, tendinous xanthomata, and premature symptoms of coronary heart disease. It is inherited as an autosomal dominant...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics